Bayer head of pharma, Stefan Oelrich, at the 10/24/2021 World Health Summit on Capitalizing on the Momentum of Innovation from COVID-19:
“We’re really taking that leap as a company in cell or gene therapy… The mRNA vaccines are an example for that cell or gene therapy. …if we had surveyed 2 years ago in the public, would you be willing to take gene or cell therapy and inject it into your body, we would have probably had a 95% refusal rate. This pandemic has opened many people’s eyes to innovation in a way that was not possible before.”